Cantor Fitzgerald’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$11.4K Buy
+12,000
New +$13.3K ﹤0.01% 756

Other funds holding LCTX

Cantor Fitzgerald's LCTX Position: Q3 2026 in Review

Cantor Fitzgerald opened a new position in Lineage Cell Therapeutics (LCTX) in Q3 2026: 12,000 shares worth $11.4K. The stake represents ﹤0.01% of the portfolio and ranks #756 among its holdings.

143 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

  • Cantor Fitzgerald held 12,000 shares of Lineage Cell Therapeutics worth $11.4K as of Q3 2026.
  • Lineage Cell Therapeutics was a new Cantor Fitzgerald position in Q3 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of Cantor Fitzgerald's portfolio in Q3 2026, its #756 holding.
  • 143 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on Cantor Fitzgerald's 13F filing for Q3 2026, filed 16 Nov 2026.